Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Emilio AlbaRamon Colomer

Abstract

To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure. The serum levels of endostatin, VEGF and bFGF were determined in postmenopausal patients with progressing MBC from serum samples obtained before initiation of letrozole. The relation between serum angiogenic factor levels and TTP was investigated. Seventy-six patients (45.2%) presented a high endostatin level (> 24.6 ng/ml), 40% low bFGF levels (0 pg/ml) and 50.4% low VEGF (=/< 187 ng/ml). With a median follow-up of 22 months, the median TTP was 12.3 months. Median TTP was worse in patients with high endostatin concentration as well as in the low bFGF group, but was not affected when VEGF was considered. When the two factors were combined, the median TTP of patients with endostatin > 24.6 ng/ml and bFGF equal 0 pg/ml was 9.5 months versus 19.5 months in patients with endostatin =/< 24.6 ng/ml and bFGF > 0 pg/ml. The baseline levels of bFGF and endostatin are predictive factors of efficacy in patients with MBC treated with letrozole and can select groups with different TTP.

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 21, 1993·International Journal of Cancer. Journal International Du Cancer·V I GuelsteinA V Ljubimov
Nov 26, 1998·The New England Journal of Medicine·C K Osborne
Jul 1, 1999·Gynecologic Oncology·L HeflerA Obermair
Oct 3, 1999·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N MiosgeR Timpl
Mar 16, 2000·The EMBO Journal·U FelborW Mothes
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R T PoonJ Wong
Feb 22, 2001·Oncology Reports·K KuroiM Toi
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H YamauchiD F Hayes
May 17, 2001·Proceedings of the National Academy of Sciences of the United States of America·L MaJ L Wallace
Oct 23, 2001·Breast Cancer : the Journal of the Japanese Breast Cancer Society·H YamauchiD F Hayes
Dec 26, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Makoto SuzukiTakehiko Fujisawa
Oct 3, 2002·Nature Reviews. Cancer·Robert Kerbel, Judah Folkman
Nov 2, 2002·Cancer·Dipok Kumar DharNaofumi Nagasue
Jul 16, 2003·Cancer Letters·Johan DixeliusLena Claesson-Welsh
Jul 31, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M NabholtzB Thürlimann
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ParidaensUNKNOWN European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBB
Jan 21, 2004·The Journal of Surgical Research·Swee H TehNiall O'Higgins
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshihiko IizasaTakehiko Fujisawa

❮ Previous
Next ❯

Citations

Jan 8, 2013·Clinical Oncology : a Journal of the Royal College of Radiologists·Hao-Yuan MoHai-Qiang Mai
Sep 5, 2017·Cancer Biomarkers : Section a of Disease Markers·Nataša Todorović-RakovićDragica Nikolić-Vukosavljević

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.